Pariet is a medication with the active ingredient rabeprazole. It is also known by other names like AcipHex in the United States. Pariet is used to reduce stomach acid and treat conditions such as gastroesophageal reflux disease (GERD) and ulcers.
The general pricing of Pariet is in the range of £0.32 – £0.43 for each pills. The amount and type of active ingredients (60 or 360 mg) determine its exact cost.
Pariet’s generic name is rabeprazole. It belongs to the class of proton pump inhibitors (PPIs) and is utilized primarily for the treatment and management of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and peptic ulcer disease. Rabeprazole comes in oral tablet form, with dosages typically available in 10 mg and 20 mg strengths.
Pariet is employed to manage conditions that result from excessive stomach acid production. Its efficacy, seen in GERD management, offers symptom relief and aids in healing erosive esophagitis. For Zollinger-Ellison syndrome, it helps regulate acid secretion. Additionally, in peptic ulcer disease, Pariet promotes ulcer healing owing to its ability to reduce gastric acid production.
Rabeprazole, the active ingredient in Pariet, functions by inhibiting the H+/K+ ATPase enzyme located on the gastric parietal cells. This action irreversibly blocks the final step of acid production, thereby decreasing stomach acid secretion and increasing gastric pH.
For GERD in adults, the usual dose is 20 mg once daily for four to eight weeks. In cases of Zollinger-Ellison syndrome, initial dosing starts at 60 mg once daily and may be adjusted based on the patient’s response and clinical condition. Peptic ulcer disease treatment typically requires 20 mg once daily for four to six weeks.
Pariet should be taken as prescribed, usually once per day. It can be taken with or without food. Tablets must be swallowed whole with water and must not be chewed, crushed, or split. Consistent timing every day enhances medication efficacy.
Usage of Pariet in pediatric patients follows specific guidelines. For children aged 1 to 11 years with GERD, the dosage is 5 to 10 mg once daily, based on the child’s weight. For patients aged 12 to 17 years, the typical dose is 20 mg once daily. Careful monitoring is essential to adjust dosages as needed.
In elderly patients, no significant adjustments in the dosage of Pariet are generally necessary. However, clinicians should consider the increased possibility of side effects and interactions due to polypharmacy in this age group and adjust therapy accordingly.
Pariet does not require dosage adjustments in patients with renal impairment. Its pharmacokinetic profile remains consistent in this population, making it a suitable treatment option without the need for modifications in dose frequency or amount.
For patients with mild to moderate hepatic impairment, rabeprazole can be used without adjustment. In cases of severe hepatic impairment, caution is advised, and therapeutic use should be closely monitored to avoid potential adverse effects.
Pariet may interact with drugs metabolized through the cytochrome P450 enzyme system. Concomitant use of anticoagulants like warfarin necessitates careful monitoring of INR levels. Rabeprazole may also decrease the efficacy of drugs requiring an acidic environment for absorption, such as ketoconazole, and increase plasma levels of drugs like methotrexate.
Common side effects of Pariet include headache, diarrhea, nausea, vomiting, and abdominal pain. Rare but serious effects may encompass hepatic dysfunction, severe dermatologic reactions, and Clostridium difficile-associated diarrhea. Long-term use potentially leads to risks such as vitamin B12 deficiency, bone fractures, and hypomagnesemia.
In the event of an overdose, standard supportive and symptomatic care should be administered. Rabeprazole does not have a specific antidote, and its effects are unlikely to be removed by dialysis. Close monitoring and supportive measures should include maintaining adequate hydration, monitoring vital signs, and engaging in gastric decontamination if indicated.
Pariet should be stored at controlled room temperature, between 15°C and 25°C (59°F to 77°F). Keep the medication in its original packaging to protect it from moisture and light. It should be kept out of reach of children and pets to prevent accidental ingestion.
Pariet is available by prescription only. Pharmacists should verify the accuracy of the prescription and counsel patients on the appropriate use of the medication. Check for potential drug interactions and ensure patients are aware of proper storage conditions and administration guidelines.
Pariet tablets contain inactive ingredients such as hydroxypropyl cellulose, mannitol, magnesium oxide, low-substituted hydroxypropyl cellulose, magnesium stearate, and iron oxide. These excipients ensure the stability, absorption, and overall efficacy of the active ingredient, rabeprazole.
Patients should be advised to take Pariet regularly and not on an as-needed basis. Encourage reporting of any side effects, especially severe or persistent symptoms. Counsel patients on the importance of adhering to the prescribed dosing schedule for optimal therapeutic outcomes. Discuss dietary modifications and lifestyle changes that may complement the medication’s efficacy.
Monitor patients regularly for therapeutic effectiveness and potential adverse effects. Check for biochemical markers such as magnesium levels, especially in long-term therapy. Routine endoscopic evaluations may be necessary in chronic conditions or in cases of inadequate response to treatment.